On Wednesday 23 November 2016 the Advanced Therapies Manufacturing Taskforce (ATMT) published a report and recommendations at the BioProcess event in Newcastle.
Cell and Gene Therapy Catapult CEO, Keith Thompson, who was attending the conference and is also a member of the taskforce, leading the technology workstream welcomed the report:
The recommendations from the advanced therapies manufacturing task force could further improve the position of the UK as an anchor for the cell and gene therapy industry. On top of the fantastic potential to tackle many unmet health needs, there’s a huge prize at stake in the form of jobs and investment so I hope that the recommendations now become a reality.
To read the full document, click here.